|
AU2013205400A1
|
|
Antigenic Polypeptides
|
|
US2011236399A1
|
|
Compositions and methods for prophylactic and therapeutic treatment of infection
|
|
US2010260752A1
|
|
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
|
US2010221237A1
|
|
Enzyme disruption of bacterial biofilms
|
|
WO2008105826A2
|
|
Compositions compromising lysostaphin variants and methods of using the same
|
|
US2007292404A1
|
|
Antimicrobial polymer conjugates
|
|
EP1994117A2
|
|
Neutralization of bacterial spores
|
|
US2007185026A1
|
|
Compositions and methods for treating bacteria
|
|
WO2007024852A2
|
|
Methods for testing vaccine candidates against bacterial infection in rodents
|
|
US2007060506A1
|
|
Compositions and methods for treating bacteria
|
|
CA2556169A1
|
|
Use of amino-oxy functional groups in the preparation of vaccines
|
|
US2004192581A1
|
|
Topical anti-infective formulations
|
|
WO2004050846A2
|
|
Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
|
|
EP1494614A1
|
|
Enzyme disruption of bacterial biofilms
|
|
WO03082926A2
|
|
Antimicrobial polymer conjugates
|
|
EP1465926A2
|
|
Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
|
|
US7250494B2
|
|
Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
|
|
US7169903B2
|
|
Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
|
|
AU2002255798A1
|
|
An animal model for enteric pathogens
|
|
CA2412026A1
|
|
Immunostimulatory rna/dna hybrid molecules
|
